Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay181 in advanced solid tumors
NCT07446816Phase 1Recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Bivalent/Multivalent Binders, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hemay181 in solid tumor (advanced stage), sponsored by Hemay Pharmaceutical Technology. Primary endpoint: Anti-tumor efficacy at 100 months. Started Dec 2025; status: recruiting.
02
Drugs
Hemay181
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07446816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446816.